Last edition
News about
Zydus Completes Enrolment for EPICS IIITM Phase 2b/3 Trial of Saroglitazar Mg
Zydus Lifesciences has completed enrolment of Phase 2b/3 EPICS IIITM trial of Saroglitazar Mg in patients with Primary Biliary Cholangitis (PBC).
SN Bioscience's SNB-101 Granted FDA Fast Track Designation for Small Cell Lung Cancer Treatment
SNB-101, previously designated as an orphan drug for SCLC and pancreatic cancer, has now received Fast Track designation, signaling a step towards potential commercialization following the completion of phase 2 clinical trials.
WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval
This approval marks a key moment as the world's first EB virus-related mRNA therapeutic cancer vaccine to receive regulatory clearance.
Flagship Pioneering and Metaphore Enter into Research Collaboration with Novo Nordisk
Metaphore Biotechnologies, in partnership with Flagship Pioneering, has inked a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.
Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors
Lupin has announced the appointment of Jeffrey Kindler and Alfonso “Chito” Zulueta as Independent Directors to its Board.
Epitor Therapeutics Unveils CasNano
Epitor Therapeutics announces the creation of CasNano, a groundbreaking ultracompact Cas protein.
The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythm
MetP Pharma Announces Preclinical Research Results of semaglutide Development
MetP Pharma has announced its preclinical research results that strongly support the further development of semaglutide in an oleogel formulation using the BrainDos drug delivery technology.
Cellipont Bioservices and Adva Biotechnology Unveil ADVA X3 Platform
Cellipont Bioservices has joined hands with Adva Biotechnology, marking the launch of the groundbreaking ADVA X3 platform in North America.
Avidity Biosciences' Delpacibart Etedesiran Receives FDA Breakthrough Therapy Designation
Despite its severity, there are currently no approved therapies for DM1, making the FDA's recognition of delpacibart etedesiran's potential all the more crucial.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy